Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994443 | 0.90 | FAAH (0.38) | DPYDALDH1A1NT5EKMT2ACCNE1 | |
| SCHEMBL23993707 | 0.86 | DPYD (0.41) | DPYDALDH1A1NT5ECCNE1CDK2 | |
| SCHEMBL23995100 | 0.84 | NT5E (0.38) | ALDH1A1NT5ECCNE1CDK2 | |
| SCHEMBL23993094 | 0.83 | NT5E (0.42) | ALDH1A1NT5EKMT2ALMNACCNE1 | |
| SCHEMBL23993079 | 0.83 | NT5E (0.42) | ALDH1A1NT5EKMT2ALMNACCNE1 | |
| SCHEMBL23993650 | 0.83 | DPYD (0.42) | DPYDALDH1A1NT5ECCNE1CDK2 | |
| SCHEMBL23993096 | 0.83 | HCRTR2 (0.35) | ALDH1A1NT5E | |
| SCHEMBL23995402 | 0.83 | NT5E (0.35) | ALDH1A1NT5ELMNACCNE1CDK2 | |
| SCHEMBL23995328 | 0.82 | NT5E (0.39) | ALDH1A1NT5ELMNAXDH | |
| SCHEMBL30224633 | 0.82 | NT5E (0.40) | ALDH1A1NT5ECCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | DPYD 23/4885ALDH1A1 347/4885NT5E 3/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | DPYD 17/4885ALDH1A1 138/4885NT5E 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.